Physician profile
Dorothy Tadder
NPI 1700075926
$3,565.49
in general payments reported to CMS, 2019-2025
22 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,583 · 2022: $583 · 2023: $539 · 2024: $488 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $860.57 | 2021-2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $472.62 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $343.89 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $303.79 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.80 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $198.12 | 2021 | |
| Glaxosmithkline, LLC. | $188.48 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $160.35 | 2023-2025 | |
| Amgen INC. | $143.74 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $137.62 | 2021-2023 | |
| Novo Nordisk INC | $123.75 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $108.26 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $69.06 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $44.65 | 2021 | |
| Boston Scientific Corporation | $44.38 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33.78 | 2021-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $24.99 | 2021 | |
| Hikma Pharmaceuticals USA | $20.03 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.71 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.90 | 2022 | |
| Horizon Therapeutics Plc | $13.90 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothy Tadder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.